HOME > 発表論文集 > 学会発表 > Clinical efficacy and safety of multi peptides dendritic cell (DC)-based vaccine manufactured by novel technique in patients with non-small cell lung cancer (NSCLC).

発表論文集

Clinical efficacy and safety of multi peptides dendritic cell (DC)-based vaccine manufactured by novel technique in patients with non-small cell lung cancer (NSCLC).

2014/09/02

 Abe H1), Sasada A1), Tabata A1), Kawasaki H2)

1) Abe Cacner Clinic

2) The Life Science Institute Co. Ltd

 

Abstract
 
[Back ground]

This study was conducted to evaluate the efficacy and safety of multi peptides DC-based vaccine in patients with non-small cell lung cancer (NSCLS).

[Methods]

DC vaccine was manufactured by novel technique without "apheresis". Multi peptides used in this study were WT1, MUC1, CEA, CA125, Survivn, Her2, NY-ESO-1 according to result of HLA typing. 34 (thirty four) advanced NSCLC patients who failed to standard therapy were enrolled in this study. DC-based vaccine was injected intradermally to the axillary or inguinal regions in 2 separate area at 6 times in 2 week interval. ELISPOT assay was performed before and at the end of one Kur of the study.

[Results]

The DC-based vaccine was well tolerated without any adverse events of grade 2 or higher. After 6 DC vaccine injected, among 34 patients with NSCLC, response rate was 26.5% and cancer control ratio was 55.9%. The patients were divided into 2 groups, one was used 2 or less peptides (group A), the other was used more than 3 peptides (group B). In group A, response rate and control ratio were 22.2% and 55.5% respectively. On the other hand, in group B, response rate and control ratio were 28.0% and 56.0% respectively. This data suggests that multi peptides pulsed DC vaccine shows better clinical outcome in terms of response rate in patients with NSCLC.

[Conclusions]

 

DC-based vaccine pulsed with multi peptides was safety and useful for the treatment of advanced NSCLC refractory to standard therapy and therefore warrants further clinical studies.

 

The Immunotherapies and Vaccine Summit 2014

August 11 - 14, 2014, Boston, USA

 

 



ページトップ

"
Copyright KUDAN